PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Pergolide mesilate - Parkinson's disease

PAD Profile : Pergolide mesilate - Parkinson's disease Important

Keywords :
dopamine agonists, ergot-derived dopamine receptor agonists, Parkinsons disease, PD
Important Information :
Not a 1st-line treatment option. On-going toxicity monitoring required

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Type
Document
Review Date

Committee Recommendations

Date
Committee Name
Narrative
06 June 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Ergot-derived Dopamine agonists (bromocriptine, pergolide, cabergoline) are NOT recommended as a first-line treatment option for Parkinson's disease and should be considered BLACK.

Ergot-derived Dopamine agonists (bromocriptine, pergolide, cabergoline) should only be considered as an adjunct to levodopa in Parkinson's disease patients:

  • who have developed dyskinesia or motor fluctuations despite optimal levodopa therapy AND
  • whose symptoms are not adequately controlled with a non-ergot derived dopamine agonist (pramipexole, ropinirole).

NOT for primary care prescribing, although all RED drug prescribing should be recorded on the patient's practice records. On-going toxicity monitoring is required.

Associated BNF Codes

04. Central Nervous System
04.09.01. Dopaminergic drugs used in parkinsonism
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More